TGFB1 and non-small cell lung carcinoma: Specifically, treatment with Andro (5.0 μM) resulted in significant suppression of HIF‐1α, TGF‐β1, Smad, and VEGF protein levels in NSCLC cell lines H1355, H1299, CL1‐0, and CL1‐5.